Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 7 other studies
7,805people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
tirzepatide
placebo or standard antihyperglycemic agents
Lowered HDL cholesterol−34%
Lowered body mass index−96%
Lowered MetS−72%
randomisedthe abstract, start to end
… lipoprotein cholesterol (OR: 0.66 [95% CI: 0.52-0.84]) to 96% reduction in the odds of elevated body mass index (OR: 0.04 [95% CI:0.02-0.08]), and 72% reduction for the odds of MetS (OR: 0.28 [95% CI: 0.24-0.33]).
← favours treatmentfavours comparator →
could be chanceDecreased high-density lipoprotein cholesteroltirzepatide vs placebo or standard antihyperglycemic agents
OR 0.660.52–0.84
Elevated body mass indextirzepatide vs placebo or standard antihyperglycemic agents
OR 0.040.02–0.08
MetS (≥3 cardiometabolic abnormalities)tirzepatide vs placebo or standard antihyperglycemic agents
OR 0.280.24–0.33
GIP/GLP-1 & amylin agonistsBody weight & compositionLipids
GIP/GLP-1 & amylin agonists × lipidshelps?settled
unlikelylikely
0.86not counted
GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated
unlikelylikely
1.00not counted
← favours comparatorfavours treatment →
1 / 6